ADC Therapeutics (ADCT) Cash from Financing Activities (2020 - 2026)
ADC Therapeutics (ADCT) posted quarterly Cash from Financing Activities of -$583000.0 for Q1 2026, down 315.13% year-on-year from $271000.0 in Q1 2025, and down 101.02% on a QoQ basis from $57.1 million in Q4 2025.
ADC Therapeutics (ADCT) Cash from Financing Activities (2020 - 2026) Analysis & Trends
ADC Therapeutics (ADCT) has reported Cash from Financing Activities for 7 consecutive years, with -$583000.0 the latest figure, recorded in Q1 2026.
- Quarterly Cash from Financing Activities fell 315.13% year-over-year to -$583000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $150.1 million (up 54.78% YoY) and the FY2025 annual result came in at $150.9 million, up 55.53% from the prior year.
- Cash from Financing Activities slipped to -$583000.0 in Q1 2026 per ADCT's latest filing, from $57.1 million in the prior quarter.
- Over the last five years, Cash from Financing Activities for ADCT reached as high as $98.7 million in Q2 2024 and fell as low as -$2.8 million in Q4 2022.
- A 5-year average of $18.8 million and a median of $271000.0 in 2025 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities jumped 29108.73% — and 2024, when it plunged 111900.0%.
- Year by year, Cash from Financing Activities stood at -$2.8 million in 2022, then jumped by 99.96% to -$1000.0 in 2023, then tumbled by 111900.0% to -$1.1 million in 2024, then jumped by 5197.23% to $57.1 million in 2025, then sank by 101.02% to -$583000.0 in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered -$583000.0, $57.1 million, and -$198000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | ADC Therapeutics | 189.60 Mn | -41.41 Mn | 17.38 Mn | -583,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -583,000.00 |
| Mar 31, 2026 | -583,000.00 |
| Dec 31, 2025 | 57.09 Mn |
| Dec 31, 2025 | 57.09 Mn |
| Sep 30, 2025 | -198,000.00 |
| Sep 30, 2025 | -198,000.00 |
| Jun 30, 2025 | 93.78 Mn |
| Jun 30, 2025 | 93.78 Mn |
| Mar 31, 2025 | 271,000.00 |
| Mar 31, 2025 | 271,000.00 |
| Dec 31, 2024 | -1.12 Mn |
| Dec 31, 2024 | -1.12 Mn |
| Sep 30, 2024 | -879,000.00 |
| Sep 30, 2024 | -879,000.00 |
| Jun 30, 2024 | 98.70 Mn |
| Jun 30, 2024 | 98.70 Mn |
| Mar 31, 2024 | 356,000.00 |
| Mar 31, 2024 | 356,000.00 |
| Dec 31, 2023 | -1,000.00 |
| Dec 31, 2023 | -1,000.00 |